Recommended Next Step in Asthma Management
For a patient already on inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) therapy who requires further treatment intensification, increase the ICS dose to high-dose while continuing the LABA, and consider adding omalizumab if the patient has allergic asthma. 1
Algorithmic Approach to Stepping Up Therapy
Step 1: Verify Current Treatment Level and Control
If the patient is on ICS/LABA combination therapy, they are at Step 3 or 4 in the NAEPP stepwise approach. Before advancing therapy:
- First, check adherence to the current regimen—this is critical as poor adherence often masquerades as treatment failure 1
- Assess environmental control measures and identify triggers
- Evaluate comorbid conditions (GERD, rhinosinusitis, obesity) that may worsen asthma control
Step 2: Determine Current ICS Dose
The next step depends on whether the patient is on:
- Low-dose ICS + LABA (Step 3) → Advance to medium-dose ICS + LABA (Step 4)
- Medium-dose ICS + LABA (Step 4) → Advance to high-dose ICS + LABA (Step 5)
Step 3: Add Adjunctive Therapy at Step 5
Once at high-dose ICS + LABA, consider adding omalizumab (Xolair) for patients with documented allergic asthma 1. This is the preferred add-on therapy before resorting to oral corticosteroids.
Step 4: Alternative Add-On Options
If omalizumab is not appropriate or available, alternative adjunctive therapies include:
- Leukotriene receptor antagonists (montelukast or zafirlukast)
- Theophylline (requires serum level monitoring)
- Zileuton (less desirable due to need for liver function monitoring) 1
Important caveat: These alternatives are less well-studied in combination with high-dose ICS/LABA compared to omalizumab 1.
Critical Safety Considerations
LABA Safety Warning
Never use LABAs as monotherapy—they must always be combined with ICS 1. The FDA issued warnings about increased severe exacerbations and deaths when LABAs are added to usual asthma therapy without adequate ICS dosing. When stepping up therapy, prioritize increasing the ICS dose alongside LABA continuation rather than adding LABA to inadequate ICS doses.
Monitoring for Inadequate Control
If the patient uses their short-acting β-agonist (SABA) more than 2 days per week for symptom relief (excluding exercise-induced bronchospasm prevention), this signals inadequate control and confirms the need to step up treatment 1.
When to Progress to Step 6
If the patient fails to achieve control on high-dose ICS + LABA + omalizumab (or alternative add-on), Step 6 involves adding oral corticosteroids 1. Before initiating chronic oral steroids:
- Consider a trial of high-dose ICS + LABA + leukotriene receptor antagonist (though this lacks clinical trial evidence) 1
- Evaluate for corticosteroid pharmacokinetic abnormalities if unable to reduce oral steroid dose below 20 mg every other day 2
- Rule out drug interactions that increase corticosteroid metabolism (rifampin, phenytoin, carbamazepine, phenobarbital) 2
Alternative Considerations
Leukotriene receptor antagonists as add-on therapy: While montelukast or zafirlukast can be added to ICS therapy, for patients 12 years and older, adding LABA is the preferred strategy over adding leukotriene modifiers 1. Leukotriene modifiers are easier to use with high compliance rates, but the evidence supporting their efficacy as add-on therapy to ICS is more limited compared to LABAs 1.
Common Pitfalls to Avoid
- Don't add multiple controller medications simultaneously—step up systematically to identify what works 1
- Don't continue ineffective alternative therapies—if an alternative treatment fails, discontinue it and use the preferred treatment before stepping up further 1
- Don't overlook allergen immunotherapy—for patients with documented allergic asthma at Steps 2-4, subcutaneous immunotherapy should be considered 1
- Don't ignore the action plan—ensure the patient has a written asthma action plan and understands when to escalate therapy 2
The evidence strongly supports a hierarchical approach: optimize ICS dosing first, maintain LABA therapy for its bronchodilator and potential steroid-sparing effects, then add targeted biologics like omalizumab before resorting to systemic corticosteroids.